SCHILKE TOBIN (CFO) sold 2.1% of their position (1.70K shares) of REVANCE THERAPEUTICS, INC. on the open market
Open‑market sale worth $42.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/5/2023ACC: 0001479290-23-000083
Officer· CFO
Since Nov 2018
-932.00
Net shares
Net seller
$42.6K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
769.00 acquired · 1.70K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+769.00
Price / share
$15.61
Trade value
$12K
% of position
1.0%
6/30/2023
80.83K→81.60K
Common Stock
Direct
Shares
−1.70K
Price / share
$25.04
Trade value
$42.59K
% of position
2.1%
7/3/2023
81.60K→79.90K
Total
Net shares
−932.00
Net value
-$30.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/30/2023 | A · Award | +769.00 | $15.61 | $12K | 1.0% | 80.83K | 81.60K |
| Common Stock Direct | 7/3/2023 | S · Sale | −1.70K | $25.04 | $42.59K | 2.1% | 81.60K | 79.90K |
| Total | −932.00 | -$30.59K | ||||||
Derivative Transactions0
No derivative transactions reported